These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 20518715)

  • 21. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
    Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
    Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.
    Hermans G; Denzer U; Lohse A; Raus J; Stinissen P
    J Autoimmun; 1999 Sep; 13(2):233-46. PubMed ID: 10479392
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.
    Teramoto K; Kontani K; Fujita T; Ozaki Y; Sawai S; Tezuka N; Fujino S; Itoh Y; Taguchi O; Kannagi R; Ogasawara K
    Cancer Immunol Immunother; 2007 Mar; 56(3):331-42. PubMed ID: 16896967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of regulatory CD4+ T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines.
    Chakraborty NG; Li L; Sporn JR; Kurtzman SH; Ergin MT; Mukherji B
    J Immunol; 1999 May; 162(9):5576-83. PubMed ID: 10228040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy.
    Bonehill A; Heirman C; Thielemans K
    J Gene Med; 2005 Jun; 7(6):686-95. PubMed ID: 15693037
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy.
    Li Y; Subjeck J; Yang G; Repasky E; Wang XY
    Vaccine; 2006 Jun; 24(25):5360-70. PubMed ID: 16714072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lessons from T cell responses to virus induced tumours for cancer eradication in general.
    Melief CJ; Kast WM
    Cancer Surv; 1992; 13():81-99. PubMed ID: 1423326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice.
    Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W
    J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
    Huang Y; Shah S; Qiao L
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficient antitumor immunity in a murine colorectal cancer model induced by CEA RNA-electroporated B cells.
    Park MY; Kim HS; Woo SJ; Kim CH; Park JS; Sohn HJ; Kim HJ; Oh ST; Kim TG
    Eur J Immunol; 2008 Aug; 38(8):2106-17. PubMed ID: 18624349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of CD4+ T cell help in cancer immunity and the formulation of novel cancer vaccines.
    Assudani DP; Horton RB; Mathieu MG; McArdle SE; Rees RC
    Cancer Immunol Immunother; 2007 Jan; 56(1):70-80. PubMed ID: 16555057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
    Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
    Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
    Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
    Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
    Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
    Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of T cell-mediated immunity using a c-Myb DNA vaccine in a mouse model of colon cancer.
    Williams BB; Wall M; Miao RY; Williams B; Bertoncello I; Kershaw MH; Mantamadiotis T; Haber M; Norris MD; Gautam A; Darcy PK; Ramsay RG
    Cancer Immunol Immunother; 2008 Nov; 57(11):1635-45. PubMed ID: 18386000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model.
    Ciesielski MJ; Kazim AL; Barth RF; Fenstermaker RA
    Cancer Immunol Immunother; 2005 Feb; 54(2):107-19. PubMed ID: 15340764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The mechanism of anti-tumor immune response against mouse melanoma to xenogeneic vaccination].
    Luo F; Mao YQ; Kan B; He QM; Jiang Y; Peng F; Yang L; Tian L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):757-60. PubMed ID: 15573746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.